Treatment of Helicobacter pylori infection 2017
Open Access
- 10 September 2017
- journal article
- review article
- Published by Wiley in Helicobacter
- Vol. 22 (S1)
Abstract
This review summarizes important studies regarding Helicobacter pylori therapy published from April 2016 to April 2017. The main themes that emerge involve studies assessing the efficacy of bismuth and nonbismuth quadruple regimens. While in recent years, much of the emphasis on the use of bismuth has focussed on its utility in a second‐line setting, an increasing number of studies this year have shown excellent efficacy in first‐line therapy. The efficacy of bismuth as a second‐line after sequential and concomitant therapy was particularly noteworthy. Antibiotic resistance was more intensely studied this year than for a long time, and definite trends are presented regarding an increase in resistance, including the fact that clarithromycin resistance in particular is now at a level where the continued use of clarithromycin triple therapy first‐line as a mainstream treatment is not recommended. Another exciting trend to emerge this year is the utility of vonoprazan as an alternative to PPI therapy, especially in resistant and difficult‐to‐treat groups.Keywords
This publication has 106 references indexed in Scilit:
- Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy forHelicobacter pylorieradication and prevention of adverse eventsUnited European Gastroenterology Journal, 2016
- Sequential Therapy or Standard Triple Therapy for Helicobacter pylori InfectionAmerican Journal of Therapeutics, 2016
- High-Level Primary Clarithromycin Resistance of Helicobacter pylori in Algiers, Algeria: A Prospective Multicenter Molecular StudyMicrobial Drug Resistance, 2016
- Efficacy of 10‐day Sitafloxacin‐Containing Third‐Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA MutationHelicobacter, 2015
- Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide SurveyHelicobacter, 2015
- Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trialGut, 2015
- Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen forHelicobacter pylorieradication: A pilot studyUnited European Gastroenterology Journal, 2015
- Practical treatment of Helicobacter pyloriEuropean Journal of Gastroenterology & Hepatology, 2014
- Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pyloriAlimentary Pharmacology & Therapeutics, 2011
- Sequential Therapy for Helicobacter pylori EradicationJournal of Clinical Gastroenterology, 2010